[ad_1]
NEW YORK, Jan. 19, 2022 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the “Global Active Pharmaceutical Ingredients (API) Industry” report — https://www.reportlinker.com/p06219466/?utm_source=GNW
Global production of APIs is largely concentrated in developing countries because of their ability to scale production based on custom and low-cost manufacturing. The API market will benefit from the growing focus on generic and branded drugs due to rising prevalence of non-communicable and chronic diseases due to changing lifestyles and rapid urbanization. The shift from traditional manufacturing techniques, increasing investments in drug discovery, and strict adherence to product quality are expected to further strengthen the market growth. The market has also benefited from the constant influx of generic drugs, which are produced after a pharmaceutical company allows it to create its own version of the drug. The COVID-19 pandemic and the resulting supply chain disruptions are driving governments to boycott APIs from China. Despite these challenges, the API market is bound to grow rapidly due to positive factors such as the pending approval of various generic and blockbuster drugs that rely on APIs.
Amid the COVID-19 crisis, the global active pharmaceutical ingredient (API) market was estimated at USD 177.5 billion in 2020 and is expected to reach a revised size of USD 265.3 billion by 2026, growing at a CAGR of 6.7%. analysis period. Innovation, one of the segments analyzed in the report, is expected to grow at a CAGR of 6.4% to reach $190.9 billion by the end of the analysis period. Following a thorough analysis of the business impact of the pandemic and the economic crisis it caused, the General Motors segment’s growth was rescaled to a revised 7.4% CAGR for the next seven-year period. This segment currently accounts for 30.2% of the global active pharmaceutical ingredient (API) market. With the expiry of patents on branded APIs, opportunities for generic APIs increase, leading to increased API market demand.
The U.S. market is expected to reach $71.5 billion in 2021, while China is expected to reach $35.4 billion by 2026
The active pharmaceutical ingredient (API) market in the U.S. is estimated to be worth $71.5 billion by 2021. The country currently holds a 36.3% share of the global market. China is the second largest economy in the world and the market size is expected to reach USD 35.4 billion by 2026, growing at a CAGR of 7.6% throughout the analysis period. Other notable geographic markets include Japan and Canada, which are expected to grow by 6.1% and 6.5%, respectively, during the analysis period. In Europe, Germany is expected to grow at a CAGR of around 6.1%, while the rest of the European market (as defined in the study) will reach $37.5 billion by the end of the analysis period. China is a major producer and exporter of APIs, accounting for about 20% of global API production. The country’s strong presence in API production can be attributed to factors such as low utility costs and strong government support. COVID-19 has highlighted various vulnerabilities associated with sourcing APIs from other regions or countries, such as broken supply chains and limited scope for immediate response to changes. These challenges are now prompting some European countries and the US to focus on relocating pharmaceutical and API production back to their home countries.
Choose a competitor (266 features in total)
- AbbVie
- aurobindo pharmaceutical co., ltd.
- BASF
- Boehringer Ingelheim International Ltd.
- cipla ltd.
- Dr Reddy’s Laboratories Ltd
- lupin co., ltd.
- Merck & Co.
- Novartis International
- Pfizer
- Sun Pharmaceutical Co., Ltd.
- Teva Pharmaceutical Industries Ltd.
- Viatris Inc.
Read the full report: https://www.reportlinker.com/p06219466/?utm_source=GNW
1. Methodology
2. Executive Summary
1. Market overview
The impact of Covid-19 and the looming global recession
2020: The Year of Disruption and Transformation
As the race between virus and vaccine intensifies, where?
Leading the world economy in 2021
Figure 1: World Economic Growth Forecast (Real GDP, Annual Percentage)
Changes from 2020 to 2022)
COVID-19 changes the pharmaceutical industry and API production
dynamics
COVID-19 puts U.S. drugmakers at risk of supply
Shortage, driving need to revamp domestic industry
structure
Pandemic leads US to focus on inventory and localization
Manufacturing corrects supply chain deficiencies
Figure 2: Percentage Breakdown of API Manufacturing Facilities
U.S. Drug Producing Countries: 2020
Increase local production capacity
COVID-19 ripple effect on API availability spurs players
Reconfigure the supply chain
COVID-19 Pandemic: A Wake-Up Call for Relief for API Seekers
supply risk
short term strategy
long-term strategy
Unprecedented global push to accelerate COVID-19 vaccine development
Developed to stimulate demand for APIs
Figure 3: Percentage of individuals globally vaccinated
Geographical Regions from 2020 to 2025
Figure 4: Number of selected vaccine manufacturing CMO sites
Country: 2020
Active Pharmaceutical Ingredients: Prelude
appearance
Regional landscape
US CDMOs to benefit from over-reliance concerns
Chinese API
China continues to remain a major hub
COVID-19 makes Europe highly dependent on APIs derived from
Outdoors in the spotlight
India strives to increase API production to self-realize
reliance on pharmaceutical production
Figure 5: Domestic Production and Import Shares of Selected API/
Indian Senior Intermediate: 2019
Global private equity firms to invest heavily in Indian mid-cap pharma
company
Recent market activity
World Brand
2. Focus on Featured Players
3. Market trends and drivers
The continuous increase in drug R&D expenditure drives the API market
Exhibit 6: Global Pharma R&D Expenditure (US$ Billion):
2015-2025
Increasing API purchases requires
Supplier of the highest quality products
Preference for professional CDMO contractors is on the rise
Strong growth in drug sales drives demand
Exhibit 7: Global Prescription Drug Sales (USD Billion)
2017, 2019, 2021, 2023 and 2025
AIC approach for faster evaluation of viable drug candidates
Drugmakers embrace digital technology amid COVID-19 crisis
Exhibit 8: $1 Billion in Digital Transformation Spending
Pharmaceutical Industry: 2020 and 2027
The growing use of artificial intelligence in drug discovery and development
Microdosing benefits high potency formulations
raw material
Growing penetration of generic drugs expands market outlook
Exhibit 9: Top US Drugs Facing Patent Expiration in 2020
Exhibit 10: Global Generic Drug Market Size (USD Billion)
2016, 2019, 2020 and 2025
Increased interest in biopharmaceuticals supports market demand
Figure 11: Global Biopharmaceutical Market Size (US$ Billion)
2019, 2022 and 2025
Rising number of biologics approvals bodes well
Figure 12: US FDA Bio-NME Approvals in 2016
by 2020
Exhibit 13: Sponsor Market Value of FDA-Approved Biologics
FDA NME (2020)
Growing Biosimilars Market Creates Opportunities for APIs
Figure 14: Global Biosimilars Market (USD Billion): 2020 and 2025
Growing focus on personalized medicine spurs demand
for complex APIs
Figure 15: Global Personalized Medicine Market: Revenue
$ million in 2019, 2021, 2023 and 2025
Increased over-the-counter sales presents an opportunity for APIs
Figure 16: Global Over-the-Counter Drugs Market Segmentation by Product
(Percent): 2020E
Rising prevalence of infectious diseases to spur growth
Figure 17: Infectious diseases remain the leading cause of death
Less Developed Regions: Breakdown of Leading Causes of Death
in sub-Saharan Africa (percentage)
Figure 18: Global deaths from infectious diseases
Disease (000s)
Rising cancer incidence and need to reduce cancer-related
Increased demand for death spells
Figure 19: Global Cancer Incidence: Number of New Cancer Cases
2018, 2020, 2025, 2030, 2035 and 2040 in millions
Figure 20: Breakdown of the total number of cancer cases worldwide
Type: 2020
Growing prevalence of chronic diseases drives market growth
Figure 21: World diabetes and demographics (2019,
2030 and 2045)
Rising Cardiovascular Disease Rates Increase Opportunities
Figure 22: Global prevalence of hypertension by region (%)
Men and women over 25
Figure 23: Heart Disease Deaths: Estimates
Percent Breakdown of Cardiovascular Disease, Ischemic
Heart disease, stroke and other
Surge in ANDA approvals bodes well
Stimulated by aging population and increasing burden of chronic disease
Pharmaceutical product sales to drive market growth
Figure 24: Statistics on the aging of the global population over the age of 65
million groups by geographic region in 2019,
2025, 2035 and 2050
4. Global Market Perspective
Table 1: Active’s current and future analysis of the world
Pharmaceutical Ingredients (API) by Geographical Region – United States,
Canada, Japan, China, Europe, Asia Pacific and Rest of World
Market – Independent Analysis of Annual Sales in Millions of Dollars
2020-2027 and % CAGR
Table 2: World History Review of Active Pharmaceuticals
Ingredient by Geographical Region (API) – United States, Canada, Japan,
China, Europe, Asia Pacific and the rest of the world –
Independent analysis of annual sales in millions of dollars over the years
2012 to 2019 and % CAGR
Table 3: 15-year outlook for global active pharmaceuticals
Composition by Geographical Region (API) – Percentage Breakdown
USA, Canada, Japan, China, Europe,
Asia Pacific and Rest of World Markets in 2012, 2021 and 2021
2027
Table 4: Current and future analysis of the world of innovation
Geographical Regions – United States, Canada, Japan, China, Europe,
Asia Pacific and Rest of World Markets – Independent Analysis
Annual sales (US$ million) from 2020 to 2027 and
The full story is available on Benzinga.com
[ad_2]
Source link
